keyword
MENU ▼
Read by QxMD icon Read
search

coinfection hiv hcv

keyword
https://www.readbyqxmd.com/read/28926562/generics-for-the-treatment-of-hepatitis-c-in-monoinfected-and-hiv-coinfected-patients-pros-and-cons
#1
Dario Cattaneo, Alessandro Fossati, Chiara Resnati, Massimo Galli, Cristina Gervasoni
The treatment of hepatitis C virus in monoinfected and HIV-coinfected patients has greatly changed over recent years as a result of the introduction of direct-acting antiviral agents (DAAs), which have revolutionized clinical outcomes and led to sustained virological response rates above 90-95%. The discovery of new molecules and the subsequent competition between pharmaceutical companies, together with the negotiated price policies pursued by many national health systems, have led to a gradual reduction in the cost of DAAs, and expand their use to an increasing number of patients, including those with mild liver damage...
September 19, 2017: AIDS Reviews
https://www.readbyqxmd.com/read/28926561/mechanisms-of-accelerated-liver-fibrosis-in-hiv-hcv-coinfection
#2
Theofilos Chrysanthidis, Georgia Loli, Simeon Metallidis, Georgios Germanidis
Although there is evidence that HCV progresses rapidly in HIV/HCV coinfected patients in comparison with HCV monoinfected, the HIV-, HCV- and host/genetic-related factors, as well as the exact mechanisms implicated in this process are not fully elucidated. Furthermore, cure of HCV in those coinfected seems possible with the new antiviral drugs, but high cost as well as insufficient identification, linkage with care and treatment hamper the achievement of this goal. Research on the subject, could reveal an important prognostic marker for the effectiveness of persuasion of patients with HIV/HCV coinfection with a predicted accelerated fibrosis course, in order to facilitate and prioritize, not in terms of guidelines but in the real life situation, their treatment with a medically just framework...
September 19, 2017: AIDS Reviews
https://www.readbyqxmd.com/read/28921677/clinical-profile-of-hepatitis-c-virus-infection-in-a-developing-country-india
#3
Ramit Mahajan, Vandana Midha, Omesh Goyal, Varun Mehta, Vikram Narang, Kirandeep Kaur, Arshdeep Singh, Dharmatma Singh, Rishu Bhanot, Ajit Sood
BACKGROUND: The epidemiology and clinical profile of hepatitis C virus (HCV) varies worldwide and data from developing countries is sparse. AIMS: To study the clinical profile of HCV infection in a developing country in South East Asia (India). METHODS: This observational study assessed patient demographics, viral characteristics, risk factors for virus acquisition and disease characteristics in HCV patients diagnosed between January 2004 and December 2015...
September 18, 2017: Journal of Gastroenterology and Hepatology
https://www.readbyqxmd.com/read/28902679/brief-report-peripheral-monocyte-macrophage-phenotypes-associated-with-the-evolution-of-cognitive-performance-in-hiv-infected-patients
#4
Massimiliano Fabbiani, Antonio Muscatello, Paolo Perseghin, Marco Bani, Arianna Incontri, Nicola Squillace, Giuseppe Lapadula, Andrea Gori, Alessandra Bandera
BACKGROUND: The contribution of monocyte activation in the development of HIV-associated neurocognitive disorders is not completely understood. This study aimed to explore the predictive value of peripheral monocyte/macrophage (M/M) phenotypes on the evolution of cognitive performance in a population of virologically suppressed HIV-infected patients. SETTING: Prospective, observational, longitudinal study. METHODS: HIV-1-infected patients with HIV-RNA <50copies/mL for >12 months underwent neuropsychological examination at baseline and after 1 year...
October 1, 2017: Journal of Acquired Immune Deficiency Syndromes: JAIDS
https://www.readbyqxmd.com/read/28902678/brief-report-high-need-to-switch-cart-or-comedication-with-the-initiation-of-daas-in-elderly-hiv-hcv-coinfected-patients
#5
Elise J Smolders, Colette Smit, Clara T M M de Kanter, Anton S M Dofferiiof, Joop E Arends, Kees Brinkman, Bart Rijnders, Marc van der Valk, Peter Reiss, David M Burger
BACKGROUND: To describe the use of nonantiretroviral comedication and combination antiretroviral therapy (cART) in patients coinfected with HIV/hepatitis C virus (HCV) and to predict the potential for drug-drug interactions (DDIs) with direct-acting antivirals (DAAs) against HCV. METHODS: This is a retrospective, cross-sectional study, using the Dutch, nationwide ATHENA observational HIV cohort database. All patients with a known HIV/HCV coinfection on January 1, 2015, were included...
October 1, 2017: Journal of Acquired Immune Deficiency Syndromes: JAIDS
https://www.readbyqxmd.com/read/28846559/sofosbuvir-based-regimens-in-hiv-hcv-coinfected-patients-after-liver-transplantation-results-from-the-anrs-co23-cupilt-study
#6
Teresa Maria Antonini, Audrey Coilly, Emilie Rossignol, Claire Fougerou-Leurent, Jérôme Dumortier, Vincent Leroy, Aurélie Veislinger, Sylvie Radenne, Danielle Botta-Fridlund, François Durand, Pauline Houssel-Debry, Nassim Kamar, Valérie Canva, Philippe Perré, Victor De Ledinghen, Alexandra Rohel, Alpha Diallo, Anne-Marie Taburet, Didier Samuel, Georges-Philippe Pageaux, Jean-Charles Duclos-Vallée
BACKGROUND: A recurrence of hepatitis C virus after liver transplantation affects survival in HIV/HCV coinfected patients. This study assessed the efficacy and safety of sofosbuvir-based regimens in HIV/HCV coinfected patients following liver transplantation. METHODS: 29 HIV/HCV coinfected transplanted patients receiving tacrolimus, cyclosporine or everolimus-based immunosuppressive therapy were enrolled in the CUPILT cohort. Their antiviral treatment combined sofosbuvir, daclatasvir with or without ribavirin (n=10/n=6), or sofosbuvir, ledipasvir with or without ribavirin (n=2/n=11)...
August 24, 2017: Transplantation
https://www.readbyqxmd.com/read/28845109/liver-stiffness-is-not-associated-with-short-and-long-term-plasma-hiv-rna-replication-in-immunocompetent-patients-with-hiv-infection-and-with-hiv-hcv-coinfection
#7
Saverio Giuseppe Parisi, Monica Basso, Carlo Mengoli, Renzo Scaggiante, Samantha Andreis, Marzia Maria Franzetti, Anna Maria Cattelan, Daniela Zago, Mario Cruciani, Massimo Andreoni, Sara Piovesan, Giorgio Palù, Alfredo Alberti
BACKGROUND: Human immunodeficiency virus (HIV) may be directly responsible for liver damage but there are contrasting data regarding the influence of detectable plasma viremia. We analyzed the influence of plasma HIV RNA (pHIV) detectability and of other clinical and viro-immunological variables on liver stiffness (LS) measurement in adult immunocompetent HIV-monoinfected patients and in patients coinfected with hepatitis C virus (HCV). METHODS: Logistic regression analysis was performed using the value of LS>7...
2017: Annals of Gastroenterology: Quarterly Publication of the Hellenic Society of Gastroenterology
https://www.readbyqxmd.com/read/28832660/a-cross-sectional-study-of-hepatitis-c-among-people-living-with-hiv-in-cambodia-prevalence-risk-factors-and-potential-for-targeted-screening
#8
Anja De Weggheleire, Sokkab An, Irith De Baetselier, Pisith Soeung, Huy Keath, Veasna So, Sreyphors Ros, Syna Teav, Bart Smekens, Jozefien Buyze, Eric Florence, Johan van Griensven, Sopheak Thai, Sven Francque, Lutgarde Lynen
The epidemiology of hepatitis C in Cambodia is not well-known. We evaluated the prevalence of hepatitis C virus (HCV) and risk factors in the HIV cohort of Sihanouk Hospital Center of Hope in Phnom Penh to strengthen the evidence for suitable HCV testing strategies among people living with HIV (PLWH) in Cambodia. All consenting adult PLWH without a history of HCV treatment were tested for HCV between November 2014 and May 2016 according to the CDC algorithm (HCV antibody II electro-chemiluminescence immunoassay, followed by COBAS® AmpliPrep/COBAS® TaqMan® HCV PCR and INNO-LIA® HCV Score immunoblot end-testing)...
2017: PloS One
https://www.readbyqxmd.com/read/28829824/a-syndemic-approach-to-assess-the-effect-of-substance-use-and-social-disparities-on-the-evolution-of-hiv-hcv-infections-in-british-columbia
#9
Zahid Ahmad Butt, Nabin Shrestha, Stanley Wong, Margot Kuo, Dionne Gesink, Mark Gilbert, Jason Wong, Amanda Yu, Maria Alvarez, Hasina Samji, Jane A Buxton, James C Johnston, Victoria J Cook, David Roth, Theodora Consolacion, Michelle Murti, Travis S Hottes, Gina Ogilvie, Robert Balshaw, Mark W Tyndall, Mel Krajden, Naveed Z Janjua
BACKGROUND: Co-occurrence of social conditions and infections may affect HIV/HCV disease risk and progression. We examined the changes in relationship of these social conditions and infections on HIV and hepatitis C virus (HCV) infections over time in British Columbia during 1990-2013. METHODS: The BC Hepatitis Testers Cohort (BC-HTC) includes ~1.5 million individuals tested for HIV or HCV, or reported as a case of HCV, HIV, HBV, or tuberculosis linked to administrative healthcare databases...
2017: PloS One
https://www.readbyqxmd.com/read/28820346/attitudes-and-potential-barriers-towards-hepatitis-c-treatment-in-patients-with-and-without-hiv-coinfection
#10
P R Allyn, S M O'Malley, J Ferguson, C H Tseng, K W Chew, D Bhattacharya
This study aimed to assess attitudes and potential barriers towards treatment in patients with hepatitis C virus (HCV) infection, comparing those with and without HIV coinfection. A cross-sectional survey of 82 HCV-infected adults with and without HIV was conducted in greater Los Angeles between November 2013 and July 2015. Overall, there were 53 (64.6%) with HIV coinfection, 20 (25.0%) with self-reported cirrhosis, and 22 (26.8%) with a history of prior HCV treatment. Of all, 93.2% wanted HCV treatment, but 45...
January 1, 2017: International Journal of STD & AIDS
https://www.readbyqxmd.com/read/28783247/bacterial-translocation-and-clinical-progression-of-hcv-related-cirrhosis-in-hiv-infected-patients
#11
N Merchante, T Aldámiz-Echevarría, M García-Álvarez, A Rivero-Juárez, J Macías, P Miralles, M A Jiménez-Sousa, M Mancebo, L Pérez-Latorre, D Pineda-Tenor, J Berenguer, S Resino, J A Pineda
The aim of the study was to evaluate whether bacterial translocation (BT) predicts the clinical outcome in HIV/HCV-coinfected patients with compensated cirrhosis. A cohort of 282 HIV/HCV-coinfected patients with cirrhosis and no previous liver decompensation (LD) was recruited. Serum levels of the DNA sequences encoding the well-conserved 16S rRNA subunit (16S rDNA), the lipopolysaccharide (LPS) and soluble CD14 (sCD14) at diagnosis of cirrhosis were measured. Primary endpoint was the emergence of the first LD and/or death of any cause...
August 7, 2017: Journal of Viral Hepatitis
https://www.readbyqxmd.com/read/28774413/management-of-hepatitis-b-in-special-populations
#12
REVIEW
Kali Zhou, Norah Terrault
Special populations infected with chronic HBV include those with decompensated cirrhosis, coinfections (HIV, HCV, HDV), hemodialysis and renal failure, immunosuppressed including transplant patients, children and women in pregnancy. These populations differ in their natural history and risk for liver-related complications, the indications for anti-HBV therapy as well as the recommendations regarding the HBV drugs used, duration of therapy and anticipated endpoints. Reflecting the special populations with substantive changes in management in recent years, this review focuses on HBV-HIV coinfected patients, immunosuppressed patients at risk for reactivation, liver transplant recipients and pregnant women...
June 2017: Best Practice & Research. Clinical Gastroenterology
https://www.readbyqxmd.com/read/28761237/membranoproliferative-glomerulonephritis-associated-with-a-human-immunodeficiency-virus-infection
#13
H Rafik, M El Amrani, D El Kabbaj
Type 1 membranoproliferative glomerulonephritis (MPGN) is an uncommon manifestation of human immunodeficiency virus (HIV)-associated renal disease in patients coinfected with hepatitis C virus. We report a case of MPGN characterized by nephrotic syndrome associated with HIV without hepatitis C coinfection. The patient had a favorable response to highly active antiretroviral therapy and angiotensin-converting enzyme inhibitors. Recognition of the MPGN lesion in HIV infection devoid of hepatitis C coinfection must be considered...
July 2017: Indian Journal of Nephrology
https://www.readbyqxmd.com/read/28759568/cannabinoid-receptor-2-63-rr-variant-is-independently-associated-with-severe-necroinflammation-in-hiv-hcv-coinfected-patients
#14
Caterina Sagnelli, Caterina Uberti-Foppa, Hamid Hasson, Giulia Bellini, Carmine Minichini, Stefania Salpietro, Emanuela Messina, Diletta Barbanotti, Marco Merli, Francesca Punzo, Nicola Coppola, Adriano Lazzarin, Evangelista Sagnelli, Francesca Rossi
OBJECTIVE: This is the first study to analyze the impact of the rs35761398 variant of the CNR2 gene leading to the substitution of GLN (Q) of codon 63 of the cannabinoid receptor 2 (CB2) with ARG (R) on the clinical presentation of chronic hepatitis in HIV/HCV coinfected patients. METHODS: Enrolled in this study were 166 consecutive HIV/HCV coinfected patients, naïve for HCV treatment. A pathologist unaware of the patients' condition graded liver fibrosis, necroinflammation (Ishak) and steatosis...
2017: PloS One
https://www.readbyqxmd.com/read/28753040/evaluation-of-sofosbuvir-velpatasvir-plus-voxilaprevir-as-fixed-dose-co-formulation-for-treating-hepatitis-c
#15
Vicente Soriano, Laura Benítez-Gutiérrez, Ana Arias, Itziar Carrasco, Pablo Barreiro, Jose M Peña, Carmen de Mendoza
The fixed-dose combination of three direct-acting antivirals (DAA), namely sofosbuvir, velpatasvir and voxilaprevir is the first pangenotypic, single tablet regimen developed for the treatment of HCV infection. Areas covered: The pharmacokinetics, pharmacodynamics, efficacy and safety of the co-formulation are reviewed. Information on drug absorption, distribution, metabolism and excretion of each of the three antivirals is evaluated. Finally, antiviral activity, safety and potential for drug interactions in phase II/III clinical trials in distinct patient populations are discussed...
July 28, 2017: Expert Opinion on Drug Metabolism & Toxicology
https://www.readbyqxmd.com/read/28723710/controlled-attenuation-parameter-and-mr-spectroscopy-measured-liver-steatosis-are-discordant-in-hiv-infected-adults-with-high-body-mass
#16
Jennifer C Price, Jennifer L Dodge, Yifei Ma, Rebecca Scherzer, Natalie Korn, Kyle Tillinghast, Marion G Peters, Susan Noworolski, Phyllis C Tien
OBJECTIVE: Hepatic steatosis (HS) is common in HIV-infected individuals. Magnetic resonance spectroscopy (MRS) is the preferred non-invasive method for HS measurement but is expensive. Controlled attenuation parameter (CAP) also assesses HS and is conveniently performed concomitantly with transient elastography. We aimed to assess the accuracy of CAP in the setting of HIV infection. DESIGN: Cross-sectional study. METHODS: CAP and MRS were performed in 82 subjects (39 HIV-monoinfected;7 HCV-monoinfected;21 HIV/HCV-coinfected; 15 with neither infection)...
July 18, 2017: AIDS
https://www.readbyqxmd.com/read/28722331/hepatitis-c-virus-and-proprotein-convertase-subtilisin-kexin-type-9-a-detrimental-interaction-to-increase-viral-infectivity-and-disrupt-lipid-metabolism
#17
REVIEW
Matteo Pirro, Vanessa Bianconi, Daniela Francisci, Elisabetta Schiaroli, Francesco Bagaglia, Amirhossein Sahebkar, Franco Baldelli
From viral binding to the hepatocyte surface to extracellular virion release, the replication cycle of the hepatitis C virus (HCV) intersects at various levels with lipid metabolism; this leads to a derangement of the lipid profile and to increased viral infectivity. Accumulating evidence supports the crucial regulatory role of proprotein convertase subtilisin/kexin type 9 (PCSK9) in lipoprotein metabolism. Notably, a complex interaction between HCV and PCSK9 has been documented. Indeed, either increased or reduced circulating PCSK9 levels have been observed in HCV patients; this discrepancy might be related to several confounders, including HCV genotype, human immunodeficiency virus (HIV) coinfection and the ambiguous HCV-mediated influence on PCSK9 transcription factors...
July 18, 2017: Journal of Cellular and Molecular Medicine
https://www.readbyqxmd.com/read/28722244/risk-of-liver-decompensation-with-cumulative-use-of-mitochondrial-toxic-nucleoside-analogues-in-hiv-hepatitis-c-virus-coinfection
#18
Vincent Lo Re Rd, Bret Zeldow, Michael J Kallan, Janet P Tate, Dena M Carbonari, Sean Hennessy, Jay R Kostman, Joseph K Lim, Matthew Bidwell Goetz, Robert Gross, Amy C Justice, Jason A Roy
PURPOSE: Among patients dually infected with human immunodeficiency virus (HIV) and chronic hepatitis C virus (HCV), use of antiretroviral therapy (ART) containing mitochondrial toxic nucleoside reverse transcriptase inhibitors (mtNRTIs) might induce chronic hepatic injury, which could accelerate HCV-associated liver fibrosis and increase the risk of hepatic decompensation and death. METHODS: We conducted a cohort study among 1747 HIV/HCV patients initiating NRTI-containing ART within the Veterans Aging Cohort Study (2002-2009) to determine if cumulative mtNRTI use increased the risk of hepatic decompensation and death among HIV-/HCV-coinfected patients...
July 19, 2017: Pharmacoepidemiology and Drug Safety
https://www.readbyqxmd.com/read/28715086/optimal-use-of-transient-elastography-and-acoustic-radiation-force-impulse-to-stage-liver-fibrosis-in-hiv-hcv-coinfected-patients-in-clinical-practice
#19
Juan José López, Núria Pérez-Àlvarez, Raul V Rodríguez, Antoni Jou, Pere Carbonell, José A Jiménez, Laura Soldevila, Montserrat Tenesa, Jordi Tor, Bonaventura Clotet, Jordi Bechini, Cristina Tural
OBJECTIVES: Liver fibrosis (LF) is crucial for the individualized management of patients with hepatitis C virus (HCV). We evaluated the concordance between two noninvasive methods for staging LF, transient elastography (TE) and acoustic radiation force impulse (ARFI), in patients coinfected with human immunodeficiency virus and HCV. We propose an algorithm for optimal use of both techniques in routine clinical practice. METHODS: A total of 89 human immunodeficiency virus/HCV-coinfected patients underwent TE and ARFI on the same day...
July 17, 2017: Journal of Ultrasound in Medicine: Official Journal of the American Institute of Ultrasound in Medicine
https://www.readbyqxmd.com/read/28715065/hypertension-dyslipidemia-and-cardiovascular-risk-in-hiv-infected-adults-in-poland
#20
Magdalena Rogalska-Płońska, Paweł Rogalski, Magdalena Leszczyszyn-Pynka, Justyna Stempkowska, Piotr Kocbach, Aldona Kowalczuk-Kot, Małgorzata Janczarek, Anna Grzeszczuk
BACKGROUND: Prevalence of cardiovascular diseases (CVD) in HIV infected patients increases with aging and duration of the disease. Hypertension (HA), high cholesterol level obesity, diabetes, tobacco exposure and use of alcohol are among the traditional risk factors that contribute to CVD. AIM: was to determinate the incidence of HA, lipid disturbances and CVD risk in dependence on clinical, viral and biochemical factors. METHODS: Four hundred and seventeen HIV infected Caucasian adult patients from the four clinical centers in Poland were enrolled and analyzed on the basis of available medical data from the years 2013-2015...
July 17, 2017: Kardiologia Polska
keyword
keyword
62586
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"